62 PART TWO | CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING References 1. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8. 2. Cohen L, de Moor CA, Eisenberg P et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503. 3. Tonato M, Roila F, Del FA, Ballatori E. Methodology of trials with antiemetics. Support Care Cancer 1996;4:281-6. 4. Roila F, Ruggeri B, Ballatori E et al. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 2014;32:101-6. 5. Wymenga AN, van der Graaf WT, Wils JA et al. A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by lowdose cisplatin- or non-cisplatin-containing chemotherapy. Ann Oncol 1996;7:505-10. 6. Gralla R, Lichinitser M, Van D, V et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-77. 7. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:1050-7. 8. Pater JL, Lofters WS, Zee B et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997;8:181-5. 9. Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer 2011;19:2063-6. 10. Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2012;20:1043-7. 11. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. The Oncologist 1999;4:191-6. 12. Herrstedt J, Roila F. Chemotherapyinduced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009;20 Suppl 4:156-8. 13. MASCC/ESMO Antiemetic Guideline 2013 14. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98.
RkJQdWJsaXNoZXIy MjY0ODMw